Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Melanoma 5Neoplasms 4Recurrence 3Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Basal Cell 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Cutaneous Squamous Cell Carcinoma 2Colorectal Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Recurrent Squamous Cell Carcinoma of Head 1Ovarian Neoplasms 1Natural Killer/T-cell Lymphoma 1Multiple Myeloma 1Malignant Solid Tumor 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Kidney Neoplasms 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × cemiplimab × Clear all
NCT03194867 2024-06-14

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Sanofi

Phase 1/2 Completed
109 enrolled 27 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡